Pegzilarginase-nbln vs Rusfertide
Overview
Pegzilarginase-nbln and Rusfertide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Pegzilarginase-nbln and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pegzilarginase-nbln | Rusfertide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 19-108 mg |
| Frequency | — | once weekly, subcutaneous |
| Reported benefits | — | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | — | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. Pegzilarginase-nbln is categorised under Weight Management & Metabolic, while Rusfertide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Pegzilarginase-nbln: FDA-approved. Rusfertide: FDA-approved.
Dosing. Typical dosing for Pegzilarginase-nbln is not catalogued. Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking Pegzilarginase-nbln and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pegzilarginase-nbln and Rusfertide?
- Pegzilarginase-nbln and Rusfertide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. Pegzilarginase-nbln is FDA-approved for one or more indications, whereas Rusfertide is FDA-approved for one or more indications.
- What is Pegzilarginase-nbln used for?
- PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take Pegzilarginase-nbln and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking Pegzilarginase-nbln and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pegzilarginase-nbln or Rusfertide FDA-approved?
- Pegzilarginase-nbln is FDA-approved for one or more indications. Rusfertide is FDA-approved for one or more indications.
Read the full articles
- Pegzilarginase-nbln — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references